Growth Hormone: Nursing Guide

Growth Hormone is a blood test that measures growth hormone (GH, also called human growth hormone or hGH) in serum. The anterior pituitary releases GH in pulses that stimulate hepatic insulin-like growth factor 1 (IGF-1) production and affect linear growth, body composition, and glucose metabolism. Measuring GH helps clinicians evaluate slow growth, suspected pituitary disorders, acromegaly monitoring, and dynamic endocrine protocols when interpreted with age, sex, symptoms, IGF-1, and stimulation or suppression test design.

Nurses encounter growth hormone testing when children have growth delay or delayed puberty, and when adults are evaluated for acromegaly. In practice, GH is released in pulses, so random measurements are rarely useful alone — GH is most informative during stimulation testing for deficiency or suppression testing after glucose load when excess is suspected.

the reporting laboratory states serum GH has limited value for assessing growth hormone secretion in normal children and recommends IGF-1 mass spectrometry as the first test for deficient or excess growth during childhood and adolescence. For acromegaly, reviewed references favor IGF-1 and IGF-binding protein panels over isolated random GH. Nurses protect validity with eight-hour fasting for serum draws, documented rest before phlebotomy, glucocorticoid review before dynamic tests, and coordination of lengthy stimulation visits that may require IV access and serial timed specimens.

Growth hormone is not a “draw anytime” result when fasting, rest, or dynamic protocol integrity is required. A child who ate breakfast, exercised before phlebotomy, or missed timed stimulation draws can push teams toward the wrong deficiency or excess conclusion. Acromegaly symptoms and hypoglycemia during testing outrank passive waiting for pending GH alone.

Document: fasting hours, rest and exercise before draw, each timed specimen, glucocorticoid exposure, growth velocity context, stimulation medicine given, and prescriber notifications.

This test can help identify:

• GH secretion pattern during supervised stimulation or glucose suppression protocols
• Need for paired IGF-1 and pituitary hormone testing when growth failure or acromegaly features align
• Treatment monitoring trends when endocrinology establishes a baseline dynamic protocol
• Support for specialist referral when results, growth velocity, and symptoms move in the same direction

This test cannot:

• Diagnose growth hormone deficiency or acromegaly from one untimed random value alone
• Replace IGF-1 as the first pediatric growth assessment marker per the reporting laboratory
• Rule out pituitary mass when the patient has new headache or vision changes — escalate clinically
• Validate supplement or anti-aging GH claims — not supported as routine nursing indication

Verify

Clarify before proceeding when:

• Order lacks protocol type but laboratory expects fasting morning GH
• Patient ate or exercised immediately before a fasting or rest-required draw
• Pediatric growth workup orders only random GH without IGF-1 per endocrine plan
• Glucocorticoids taken without documented hold instructions before dynamic testing
• Timed stimulation or suppression draw was missed or mislabeled
• New headache, vision changes, or jaw pain appear during outpatient collection planning
• Specimen label time does not match actual draw time

Integrate GH with IGF-1, documented fasting and rest, growth velocity, puberty staging, and whether the sample was random or part of stimulation/suppression. One value is rarely decisive — evaluate outcomes after valid repeat sampling or specialist review.

Diagnostic safety badge: Critical-result test — prompt review and escalation may be required when IGF-1 and GH guide specialist referral or when acromegaly symptoms emerge.

Check-before-test protocol

1. Identity + correct protocol type (serum vs stimulation vs suppression)
2. Fasting and rest status confirmed with teach-back
3. Age, sex, and growth velocity context documented
4. IGF-1 and paired pituitary labs coordinated
5. Acromegaly symptom screen before outpatient collection

Critical teach-back questions

• “Can you tell me when your child last ate or drank anything other than water?”
• “What headache, vision, or jaw symptoms should you report before we wait for lab results?”
• “Do you understand the stimulation visit may take several hours and requires fasting?”

Care coordination: pediatric or adult endocrinology, laboratory/phlebotomy, infusion clinic for dynamic tests, radiology for bone age or pituitary imaging per prescriber, and rapid response per institutional protocol.

• Is this random fasting GH, IGF-1, stimulation, or glucose suppression?
• Was the patient fasting and rested before the draw?
• What IGF-1 result pairs with this GH sample?
• Did glucocorticoids, stress, or exercise affect pre-test conditions?
• Does the patient need acromegaly or hypoglycemia escalation now regardless of pending labs?

Growth hormone testing is ordered when clinicians need biochemical data about pituitary GH secretion beyond growth charts alone — always paired with clinical context and often with IGF-1 or dynamic protocols.

There is no absolute contraindication to GH specimen collection, but nurses must not proceed with dynamic stimulation or suppression when fasting, rest, or medication instructions were not met if that would invalidate endocrine decisions.

Preparation depends on whether the order is fasting serum GH, IGF-1, stimulation testing, or glucose suppression — verify protocol before educating the patient.

This page is a Tests & Diagnostics guide for Growth Hormone. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).

Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.

Nursing workflow on this page — from order to safe action on results:

Serum GH is commonly reported in ng/mL (µg/L). Interpretation requires the reporting laboratory reference interval, patient age and sex, documented fasting and rest, whether the sample was random or part of a dynamic protocol, and paired IGF-1 when available.

Universal numeric critical-value thresholds for random serum GH are Turnaround and screening rules vary by institution; follow local institutional policy. Urgent nursing action depends on dynamic protocol results, IGF-1 trends, acromegaly symptoms, and local laboratory critical-result policy.

GH immunoassays are sensitive to pulsatile secretion, stress, exercise, fasting status, and age. Nurses prevent false reassurance or false alarm by protecting pre-analytic quality and documenting context.

Nursing responsibilities center on protocol verification, fasting and rest teaching, dynamic-test monitoring, and clear communication when pre-analytic conditions were not met.

Documentation should prove protocol integrity and support endocrine interpretation.

Use plain language while keeping fasting, rest, and follow-up expectations clear — especially for pediatric families.

Practice NCLEX-style clinical judgment focused on Growth Hormone safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.

About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.

Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Growth Hormone.

Policies: Medical Review Process · Editorial Policy · Correction Policy